LMWH for DVT Prophylaxis in Hospitalized Bedridden Patients
For hospitalized bedridden medical patients, use enoxaparin 40 mg subcutaneously once daily or dalteparin 5,000 units subcutaneously once daily for DVT prophylaxis, continuing throughout hospitalization or until the patient is fully ambulatory. 1, 2, 3
Standard Prophylactic Dosing
The recommended LMWH regimens for hospitalized medical patients are:
- Enoxaparin: 40 mg subcutaneously once daily 1, 2, 4
- Dalteparin: 5,000 units subcutaneously once daily 1, 2, 4
- Tinzaparin: 4,500 units (fixed dose) or 75 units/kg subcutaneously once daily 2
Alternative: Unfractionated heparin 5,000 units subcutaneously every 8 hours (though every 12 hours appears less effective) 1, 3
The once-daily LMWH regimens are preferred over unfractionated heparin because they reduce healthcare worker exposure, minimize missed doses, and have lower rates of heparin-induced thrombocytopenia 5. Continue prophylaxis for the duration of hospitalization or until the patient becomes fully ambulatory 1.
Dose Adjustments for Renal Impairment
Creatinine Clearance <30 mL/min (Severe Renal Impairment)
For enoxaparin specifically: Reduce dose to 30 mg subcutaneously once daily 2. This is the only LMWH with FDA-approved dosing guidance for severe renal impairment.
For other LMWHs with CrCl <30 mL/min: Either switch to unfractionated heparin 5,000 units subcutaneously every 8-12 hours, or use anti-factor Xa monitoring if continuing LMWH 1, 2. The target prophylactic anti-Xa level is 0.2-0.4 IU/mL, measured 4-6 hours after the third or fourth dose 2.
Creatinine Clearance 30-50 mL/min (Moderate Renal Impairment)
Use caution and consider dose reduction or monitoring, particularly if treatment extends beyond 10 days 2, 6. Some evidence suggests enoxaparin accumulation begins at CrCl <50 mL/min, with renal clearance reduced by 31% in this range 2. Consider anti-factor Xa monitoring for prolonged use in this population 6.
Special Considerations for Tinzaparin
Avoid tinzaparin entirely in patients aged >70 years with renal insufficiency 2. A randomized trial showed substantially higher mortality (11.2% vs 6.3%, P=0.049) in elderly patients with CrCl <60 mL/min receiving tinzaparin compared to unfractionated heparin 2.
Dalteparin in Renal Impairment
Dalteparin shows less accumulation than enoxaparin in renal impairment. Studies demonstrate no bioaccumulation with prophylactic dalteparin 5,000 units daily even in severe renal impairment (CrCl <30 mL/min) 2. However, for extended treatment (not prophylaxis), monitor peak anti-Xa levels targeting 0.5-1.5 IU/mL if CrCl <30 mL/min 2.
Key Clinical Pitfalls
Calculate creatinine clearance using the Cockcroft-Gault equation, not estimated GFR, as this is what was used in clinical trials and provides more accurate assessment for drug dosing 6.
Reassess renal function regularly during hospitalization, as acute illness can cause fluctuating kidney function that changes LMWH clearance 2.
Do not routinely monitor anti-factor Xa levels in patients with normal renal function receiving standard prophylactic doses—monitoring is reserved for severe renal impairment, morbid obesity (>190 kg), or prolonged use (>10 days) in moderate renal impairment 2, 6.
Contraindications to pharmacologic prophylaxis include active bleeding, platelet count <50,000/mcL, severe platelet dysfunction, recent major surgery at high bleeding risk, and hemorrhagic coagulopathy 2. In these cases, use mechanical prophylaxis with intermittent pneumatic compression 3, 7.
Duration and Monitoring
Continue prophylaxis throughout the hospital stay or until the patient is fully ambulatory 1. Extended prophylaxis beyond discharge is generally not recommended for most medical patients 3, though it may be considered for select high-risk patients (age >75, active cancer, or prior VTE history) 8.
Monitor hemoglobin, hematocrit, and platelet count every 2-3 days up to day 14, then every 2 weeks or as clinically indicated to detect heparin-induced thrombocytopenia or bleeding 2.